Entasis Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens. Co.'s main product candidate, sulbactam-durlobactam, is an intravenous (IV), combination of sulbactam, an IV ß-lactam antibiotic, and durlobactam, an intravenous ß-lactamase inhibitor, that Co. is developing for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. Co.'s second late-stage product candidate, zoliflodacin, is an orally administered molecule being developed for the treatment of uncomplicated gonorrhea. We show 17 historical shares outstanding datapoints in our ETTX shares outstanding history coverage, used to compute ETTX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ETTX market cap history over the course of time is important for investors
interested in comparing ETTX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ETTX versus a peer is one thing; comparing
ETTX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ETTX can fluctuate over the course of history.
With this page we aim to empower investors researching ETTX by allowing them to research the ETTX market cap history. |
Free ETTX Email Alerts:
Video: The Importance of Market Cap
